HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.

AuthorsGuillermo L Rivell, Chris Y Brunson, Laura Milligan, Robert K Stuart, Luciano J Costa
JournalAmerican journal of hematology (Am J Hematol) Vol. 86 Issue 8 Pg. 699-701 (Aug 2011) ISSN: 1096-8652 [Electronic] United States
PMID21630309 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Boronic Acids
  • Immunologic Factors
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Cyclophosphamide
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, therapeutic use)
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Cyclophosphamide (administration & dosage, adverse effects, therapeutic use)
  • Drug Resistance, Neoplasm
  • Hospitals, University
  • Humans
  • Immunologic Factors (therapeutic use)
  • Leukemia, Plasma Cell (drug therapy)
  • Middle Aged
  • Multiple Myeloma (drug therapy)
  • Protease Inhibitors (therapeutic use)
  • Pyrazines (therapeutic use)
  • Retrospective Studies
  • Salvage Therapy (adverse effects)
  • Severity of Illness Index
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: